Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia

American Journal of Psychiatry

Volumn 155, Issue 9, 1998, Pages 1207-1213

  Tsai, Guochuan ^a   Goff, Donald C ^a   Chang, Robert W ^a   Flood, James ^a   Baer, Lee ^a   Coyle, Joseph T ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; GLUTAMIC ACID; GLYCINE; LIPID HYDROPEROXIDE; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; NEUROLEPTIC AGENT; SUPEROXIDE DISMUTASE;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; NEUROTRANSMISSION; OXIDATIVE STRESS; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOMATOLOGY; TARDIVE DYSKINESIA;

EID: 0031695231     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.155.9.1207     Document Type: Article

References (46)

1. Morgenstern H, Glazer WM: Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Arch Gen Psychiatry 1993; 50:723-733
2. Jenner P, Marsden CD: Is the dopamine hypothesis of tardive dyskinesia completely wrong? Trends Neurosci 1986; 9:259-260
3. Cadet JL, Lohr JB: Possible involvement of free radicals in neuroleptic-induced movement disorders: evidence from treatment of tardive dyskinesia with vitamin E. Ann NY Acad Sci 1989; 570:176-185
4. Rastogi SK, Rastogi RB, Singhal RL, Lapierre YD: Behavioral and biochemical alterations following haloperidol treatment and withdrawal: the animal model of tardive dyskinesia reexamined. Prog Neuropsychopharmacol Biol Psychiatry 1983; 7:153-164
5. Crow TJ, Cross AJ, Johnstone EC, Owen F, Owens DG, Waddington JL: Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? are they associated with changes in dopamine receptors? J Clin Psychopharmacol 1982; 2:336-340
6. Christensen E, Moller JE, Faurbye A: Neuropathological investigation of 28 brains from patients with dyskinesia. Acta Psychiatr Scand 1970; 46:14-23
7. Gunne LM, Andren PE: An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia. Clin Neuropharmacol 1993; 16:90-95
8. Nielsen EB, Lyon M: Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (flupenthixol) in rats. Psychopharmacology (Berl) 1978; 59:85-89
9. Pakkenberg H, Fog R, Nilakantan B: The long-term effect of perphenazine enanthate on the rat brain: some metabolic and anatomical observations. Psychopharmacologia 1973; 29: 329-336
10. Anderson U, Haggstrom JE, Levin ED, Bondesson U, Valverius M, Gunne LM: Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia. Mov Disord 1989; 4:37-46
11. Gunne LM, Haggstrom JE: Experimental tardive dyskinesia. J Clin Psychiatry 1985; 46:48-50
12. Gunne LM, Haggstrom JE, Sjoquist B: Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 1984; 309:347-349
13. Carlsson M, Carlsson A: Interaction between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci 1990; 13:272-276
14. Bardgett ME, Wrona CT, Newcomer JW, Csernansky JG: Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics. Eur J Pharmacol 1993; 230:245-250
15. Perry TL, Hansen S, Kish SJ: Effects of chronic administration of antipsychotic drugs on GABA and other amino acids in the mesolimbic area of rat brain. Life Sci 1979; 24:283-288
16. Olney JW: Excitotoxic amino acids and neuropsychiatric disorders. Annu Rev Pharmacol Toxicol 1990; 30:47-71
17. Coyle JT, Puttfarcken P: Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993; 262:689-695
18. Mitchell IJ, Lawson S, Moser B, Laidlaw SM, Cooper AJ, Walkinshaw G, Waters CM: Glutamate-induced apoptosis results in a loss of striatal neurons in the parkinsonian rat. Neuroscience 1994; 63:1-5
19. Volterra A, Trotti D, Tromba C, Floridi S, Racagni G: Glutamate uptake inhibition by oxygen free radicals in rat cortical astrocytes. J Neurosci 1994; 14:2924-2932
20. Burkhardt C, Kelly JP, Lim YH, Filley CM, Parker WD Jr: Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 1993; 33:512-517
21. Jackson-Lewis V, Przedborski S: Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 1994; 35:244-245
22. Simonian NA, Coyle JT: Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 1996; 36:83-106
23. Schooler NR, Kane JM: Research diagnoses for tardive dyskinesia (letter). Arch Gen Psychiatry 1982; 39:486-487
24. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
25. Goff DC, Tsai G, Beal MF, Coyle JT: Tardive dyskinesia and substrates of energy metabolism in CSF. Am J Psychiatry 1995; 152:1730-1736
26. Tsai G, Cork LC, Stauch B, Coyle JT: Abnormal acidic amino acids and N-acetylaspartylglutamate in hereditary canine motor neuron disease. Brain Res 1993; 629:305-309
27. Puttfarcken PS, Getz RL, Coyle JT: Kainic acid-induced lipid peroxidation: protection with butylated hydroxytoluene and U78517F in primary cultures of cerebellar granular cells. Brain Res 1993; 624:223-232
28. Vevine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz A-G, Ahn BW, Shaltiel S, Stadtman ER: Determination of carbonyl content in oxidatively modified protein, in Methods in Enzymology. Edited by Packer L, Glazer AN. New York, Academic Press, 1990, pp 464-478
29. Meshul CK, Casey DE: Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Res 1989; 489:338-346
30. Gattaz WF, Gattaz D, Beckmann H: Glutamate in schizophrenics and healthy controls. Arch Psychiatr Nervenkr 1982; 231:221-225
31. Daly DA, Moghaddam B: Actions of clozapine and haloperidol on the extracellular levels of excitotory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 1993; 152:61-64
32. Halliwell B: Reactive oxygen species and the central nervous system. J Neurochem 1992; 59:1609-1623
33. Cadet JL, Perumal AS: Chronic treatment with prolixin causes oxidative stress in rat brain. Biol Psychiatry 1990; 28:738-740
34. Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV: Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990; 28:535-539
35. Pall HS, Williams AC, Blake DR, Lunec J: Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet 1987; 2:596-599
36. Schwartz PJ, Reaume A, Scott R, Coyle JT: Effects of over- and under-expression of Cu,Zn-superoxide dismutase on toxicity of glutamate analogs in transgenic mouse striatum. Brain Res 1998; 789:32-39
37. Mukherjee S, Mahadik SP, Correnti EE, Scheffer R: The anti-oxidant defense system at the onset of psychosis. Biol Psychiatry 1994; 35:701-708
38. Mion CC, Andreasen NC, Arndt S, Swayze VW II, Cohen GA: MRI abnormalities in tardive dyskinesia. Psychiatry Res 1991; 40:157-166
39. Jeste DV, Lohr JB, Manley M: Study of neuropathologic changes in the striatum following 4, 8, and 12 months of treatment with fluphenazine in rats. Psychopharmacology (Berl) 1992; 106:154-160
40. Johansson PE: Methylazoxymethanol (MAM)-induced brain lesion and oral dyskinesia in rats. Psychopharmacology (Berl) 1990; 100:72-76
41. Rothstein JD, Tsai G, Kuncl RW, Clawson L, Cornblath DR, Drachman DB, Pestronk A, Stauch B, Coyle JT: Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990; 28:18-25
42. Tsai G, Coyle JT: N-Acetylaspartate in neuropsychiatric disorders. Prog Neurobiol 1995; 46:531-540
43. Adler LA, Peselow E, Rotrosen J, Duncan E, Lee M, Rosenthal M, Angrist B: Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 1993; 150:1405-1407
44. Egan MF, Hyde TM, Albers GW, Elkashef A, Alexander RC, Reeve A, Blum A, Saenz RE, Wyatt RJ: Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992; 149:773-777
45. Lohr JB, Caligiuri MP: A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 1996; 57:167-173
46. Peyser CE, Folstein M, Chase GA, Starkstein S, Brandt J, Cockrell JR, Bylsma F, Coyle JT, McHugh PR, Folstein SE: A trial of d-α-tocopherol in Huntington's disease. Am J Psychiatry 1995; 152:1771-1775